Court Ruling Against Utah Company Is Good News for Pathway Genomics

The ruling in Utah helps San Diego-based Pathway Genomics Corp

An appeals court has ruled against Salt Lake City-based Myriad Genetics Inc. regarding its gene sequencing patents used for breast and ovarian cancers. This ruling is not only good for defendant Ambry Genetics Corp., but for San Diego-based Pathway Genomics Corp., which has also been sued by Myriad.

The appeals court said three patents on the tests never should have been issued.

The patents cover products of nature that aren’t eligible for legal protection, the U.S. Court of Appeals for the Federal Circuit said in an opinion posted on the court’s docket. The court upheld a trial judge’s decision to allow the competing tests, including those made by Ambry to remain on the market.
  [[283098621,C]]

Contact Us